Return to Course LibraryCE InformationPrint Course Materials


E. Michael Lewiecki, MD, FACP, FACE, CCD
Director, New Mexico Clinical Research & Osteoporosis Center

Clinical Assistant Professor of Medicine
University of New Mexico Health Sciences Center
Albuquerque, NM



PC: Win7/Win8, Pentium processor or faster, at least 2GB RAM, Internet Explorer version 10/11, Mozilla FireFox version 33.0.

MAC: OS version 10.8/10.9, Intel processor, at least 2GB RAM, Safari version 6.2, FireFox 33.0

5104-502 Bone Densitometry Update: DXA Quality Matters


A free live webinar with Dr. Michael Lewiecki for radiologists, clinical densitometrists, rheumatologists, endocrinologists, orthopaedists, radiologic technologists, nurses, and referring physicians



Wednesday • October 2, 2019
7:00 pm EASTERN | 6:00 pm CENTRAL
5:00 pm MOUNTAIN | 4:00 pm PACIFIC

Format: Live Webinar
Credit: 1.0 AMA PRA Category 1
  1.0 ANCC Contact hour
  1.0 ARRT Category A
Tuition:  free


Course Overview
Osteoporosis continues to be a major public health concern in the United States. Although osteoporosis can be prevented and treated, the disease continues to be underdiagnosed and undertreated, resulting in patients not receiving the benefits of therapy or life style changes in the early phase of the disease when intervention is most effective.[1, 2] Estimates show that for US women age 55 and older, the hospitalization burden of osteoporosis and related medical costs is greater than of myocardial infarction, stroke, or breast cancer.[2]

The Expert Panel on Musculoskeletal Imaging of the American College of Radiology reports that 50% of women and 20% of men 50 years or older will experience a bone fracture, with a 20% mortality rate within the first year. This Expert Panel also writes that the projected direct cost of hip fracture is $67.7 billion by 2020.[3]

Measuring bone mineral density (BMD) benefits both the patient and society given the potential of BMD measurement for reducing mortality and morbidity, as well as the personal and financial costs, of osteoporosis-associated fractures when they are detected and treated early. Bone densitometry is the only technology currently available that accurately measures bone mass or predicts fracture risk.[3]

Dr. Lewiecki’s lecture and case studies will include: the current state and impact of osteoporosis and fracture on public health; the use of DXA and other technologies for identifying osteoporosis; the clinical relevance of bone densitometry in treatment decisions, and recent updates to the International Society for Clinical Densitometry official positions as applied to clinical practice.

1. Clinician’s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation website. Accessed August 14, 2019.

2.   Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90(1):53-62.

3. American College of Radiology website. ACR Appropriateness Criteria®. Osteoporosis and Bone Mineral Density.  Accessed August 14, 2019.

Educational Objectives
At the conclusion of this activity, participants should be better able to:

  • Explain the public health importance of osteoporosis
  • Compare dual-energy X-ray absorptiometry (DXA) with other technologies for assessing musculoskeletal health
  • Demonstrate the importance of precision assessment for serial bone density tests
  • Describe the clinical applications of DXA
  • Review common pitfalls in DXA interpretation

CME/CE Credit
Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live event and e-learning materials.

For more information go to

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hour of ARRT Category A continuing education credit.

How to Enroll and Participate
This program is offered by ICPME through WebEx webinar service at no charge to the learner. Credit cannot be granted for group viewing. To receive credit, each attendee must sign in on a separate computer.

  • Click ENROLL NOW and follow the registration instructions to register with ICPME.
  • You will receive an email from ICPME confirming your registration.
  • At the end of the registration process, click on ACCESS WEBINAR.
  • Detailed log-in instructions will be sent to you via e-mail the day before the webinar.

How to Receive Credit

  • To receive credit, each participant must attend the entire session and complete the postcourse evaluation.
  • Upon verification of your participation from the WebEx event report, you will receive an email from ICPME two weeks after the event with instructions to print your certificate of credit. You will not be able to print your certificate until that time.

Your certificate of credit will remain in your account at as a permanent record of your participation.

E. Michael Lewiecki, MD, FACP, FACE, CCD
Director, New Mexico Clinical Research & Osteoporosis Center
Clinical Assistant Professor of Medicine
University of New Mexico Health Sciences Center
Albuquerque, NM

Dr. Lewiecki is Director of New Mexico Clinical Research & Osteoporosis Center and Clinical Assistant Professor of Medicine at University of New Mexico Health Sciences Center.  He is a consultant in osteoporosis and metabolic bone disease, supervisor of bone densitometry at his center, and an educator with a special interest in the management of osteoporosis and metabolic bone disease. He is principal investigator for the center’s osteoporosis clinical trials and author of numerous scientific publications on osteoporosis and bone densitometry.

He is founder and Director of Bone Health TeleECHO (Extension for Community Healthcare Outcomes), an ongoing videoconferencing program for healthcare professionals focusing on osteoporosis and metabolic bone diseases. This was developed through collaboration of the ECHO Institute at the University of New Mexico Health Sciences Center and the Osteoporosis Foundation of New Mexico. It is proof-of-concept for a strategy to expand global capacity to deliver best practice skeletal health care.

Dr. Lewiecki is vice president of the National Osteoporosis Foundation and past-president of the International Society for Clinical Densitometry. He is founding president of the Osteoporosis Foundation of New Mexico and program director of its flagship activity, the annual Santa Fe Bone Symposium.

Disclosure Information
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

E. Michael Lewiecki, MD, FACP, FACE, CCD has no disclosures to report.

ICPME and PIM planners and managers have no disclosures to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

For questions regarding this program, please contact ICPME:
Phone: 607-257-5860 X10

Jointly provided by


This activity is supported by an independent educational grant from Hologic, Inc.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.